MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Biocept Total Non Current Liabilities 2011-2026 | BIOC
Annual Total Non Current Liabilities Biocept
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 11.3 M | 973 K | 1.1 M | 1.42 M | 2.53 M | 3.55 M | 5.38 M | 462 K | 1.26 M | 1.93 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.3 M | 462 K | 2.99 M |
Quarterly Total Non Current Liabilities Biocept
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 973 K | 1.03 M | 983 K | 1.45 M | 1.1 M | 1.17 M | 1.26 M | 1.36 M | 1.42 M | 1.26 M | 1.56 M | 2.06 M | 2.53 M | 2.79 M | 3.13 M | 3.13 M | 3.55 M | 3.88 M | 4.23 M | 5.08 M | 5.35 M | 5.31 M | 5.18 M | 473 K | 462 K | 167 K | 509 K | 1.25 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.35 M | 167 K | 2.24 M |
Total Non Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
7.58 M | $ 22.11 | - | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
61.1 M | $ 22.36 | 17.07 % | $ 241 M |  China |
 |
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
BioNano Genomics
BNGO
|
16.4 M | $ 1.6 | - | $ 2.03 M | USA |
 |
Castle Biosciences
CSTL
|
2.76 M | $ 40.61 | 1.35 % | $ 1.13 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M |  Britain |
 |
Co-Diagnostics
CODX
|
3.56 M | $ 6.03 | - | $ 177 M | USA |
 |
DarioHealth Corp.
DRIO
|
25.8 M | $ 12.13 | -10.01 % | $ 344 M | Israel |
 |
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | USA |
 |
Fulgent Genetics
FLGT
|
2.26 M | $ 28.01 | 7.77 % | $ 847 M | USA |
 |
Danaher Corporation
DHR
|
26.9 B | $ 235.57 | - | $ 172 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | China |
 |
DexCom
DXCM
|
1.15 B | $ 70.1 | - | $ 27.1 B | USA |
 |
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
559 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | China |
 |
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | USA |
 |
Exact Sciences Corporation
EXAS
|
981 M | $ 101.63 | - | $ 18.8 B | USA |
 |
CareDx, Inc
CDNA
|
17.9 M | $ 18.9 | - | $ 1.02 B | USA |
 |
Celcuity
CELC
|
69.2 K | $ 109.17 | 3.95 % | $ 4.31 B | USA |
 |
Anixa Biosciences
ANIX
|
4.17 M | $ 3.28 | - | $ 105 K | USA |
 |
Guardant Health
GH
|
91.4 M | $ 109.93 | - | $ 13.5 B | USA |
 |
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
13 B | $ 244.29 | 1.58 % | $ 44.3 B | USA |
 |
Illumina
ILMN
|
2.04 B | $ 150.14 | - | $ 23.9 B | USA |
 |
Charles River Laboratories International
CRL
|
2.35 B | $ 216.77 | - | $ 11.1 B | USA |
 |
Mettler-Toledo International
MTD
|
1.61 B | $ 1 470.87 | - | $ 31.2 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
107 M | $ 6.63 | - | $ 601 M | USA |
 |
National Research Corporation
NRC
|
39.6 M | $ 18.9 | -2.07 % | $ 464 M | USA |
 |
Natera
NTRA
|
124 M | $ 254.4 | - | $ 25 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 178.14 | - | $ 19.8 B | USA |
|
Biodesix
BDSX
|
62.1 M | $ 5.96 | -1.16 % | $ 773 M | USA |
 |
OPKO Health
OPK
|
642 M | $ 1.36 | - | $ 944 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 253.73 | - | $ 21.3 B | USA |
 |
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
461 M | $ 202.92 | - | $ 16.7 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
630 M | $ 714.55 | - | $ 58.9 B | USA |
 |
Lantheus Holdings
LNTH
|
225 M | $ 69.37 | -0.44 % | $ 4.8 B | USA |
 |
Agilent Technologies
A
|
3.29 B | $ 147.81 | 0.14 % | $ 44.9 B | USA |
 |
Biomerica
BMRA
|
1.57 M | $ 2.78 | 5.41 % | $ 6.39 M | USA |
 |
Bioventus
BVS
|
238 M | $ 7.61 | -0.52 % | $ 477 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
8.08 B | $ 29.12 | - | $ 20 B |  Niderland |
 |
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | Israel |